Intranasal oxytocin for apathy in people with frontotemporal dementia (FOXY): a multicentre, randomised, double-blind, placebo-controlled, adaptive, crossover, phase 2a/2b superiority trial
Kristy Coleman(Lawson Health Research Institute), Elizabeth Finger(Western University), Adam L. Boxer(University of California, San Francisco), Scott Berry(Queen's University), Kimiko Domoto-Reilly(University of Washington), Chloe Stewart(St Joseph's Health Care), Anton P. Porsteinsson(University of Rochester), Howard Feldman(University of British Columbia), Sachin Pandey(London Health Sciences Centre), Chiadi U. Onyike(Johns Hopkins University), Michael Mayich(London Health Sciences Centre), Ging‐Yuek Robin Hsiung(University of British Columbia), Michelle A. Detry(Berry & Associates (United States)), Edward D. Huey(New York Psychoanalytic Society and Institute), Anna McGlothlin(Berry & Associates (United States)), Miguel Restrepo-Martínez(Western University), Ramiro Ruiz‐Garcia(Instituto Nacional de Neurología y Neurocirugía), Mario Masellis(Sunnybrook Health Science Centre), Robert Laforce(Université Laval), Nathan Herrmann(Sunnybrook Health Science Centre), Simon Ducharme(Montreal Neurological Institute and Hospital), Jeffrey Cummings(Cleveland Clinic), Bryan Dias(London Health Sciences Centre), Stephen Pasternak(Western University), Anna Bosse(Berry & Associates (United States)), Maria Carmela Tartaglia
Cited by 17
Related Papers
Diagnosis and management of dementia with Lewy bodies
|Neurology|2017|4.4k
Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria
|Movement Disorders|2017|2.3k
Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17
|Nature|2006|2.1k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria
|Alzheimer s & Dementia|2016|1.9k